Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

2.60
-0.0900-3.35%
Post-market: 2.630.0300+1.15%16:45 EDT
Volume:733.97K
Turnover:1.91M
Market Cap:359.53M
PE:-6.49
High:2.69
Open:2.68
Low:2.53
Close:2.69
Loading ...

Positive Buy Rating for Tovecimig-Paclitaxel Combo Following Promising COMPANION-002 Trial Results

TIPRANKS
·
02 Apr

Compass Therapeutics Inc. : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $6 From $4

THOMSON REUTERS
·
02 Apr

BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters
·
01 Apr

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate

MT Newswires Live
·
01 Apr

Tovecimig (Ctx-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients With Biliary Tract Cancer

THOMSON REUTERS
·
01 Apr

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns

Simply Wall St.
·
30 Mar

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest

Simply Wall St.
·
18 Mar

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Analysts’ Top Healthcare Picks: Compass Therapeutics (CMPX), LENSAR (LNSR)

TIPRANKS
·
28 Feb

Compass Therapeutics Q4 EPS $(0.11) Misses $(0.10) Estimate

Benzinga
·
27 Feb

Compass Therapeutics reports Q4 EPS (11c), consensus (9c)

TIPRANKS
·
27 Feb

Compass Therapeutics Inc.: 2024-End Cash & Marketable Securities Expected to Provide Cash Runway Into Q1 2027

THOMSON REUTERS
·
27 Feb

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
27 Feb

Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target

MT Newswires Live
·
24 Feb

Compass Therapeutics Inc. : Guggenheim Initiates Coverage With Buy Rating; Price Target $12

THOMSON REUTERS
·
24 Feb

Compass Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
24 Feb

Piper Sandler Initiates Compass Therapeutics at Overweight

MT Newswires Live
·
19 Feb

BUZZ-Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating

Reuters
·
19 Feb